Modified hTERT treatment ameliorates pressure overload-induced heart failure
This research was supported by the National Natural Science Foundation of China (82070248, 82300282, 82300476), the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (0900000024), 2023 Shanghai Action Plan for Promoting Scientific and Technological Innovation and Industrial Development of Gene Therapy (23J11900600).
Authors
- E. J. Ashley
- Qingying Yu (ORCID: https://orcid.org/0000-0001-5692-2766)
- Weiyao Xiong
- Xiaolu Bao
- Ye Wang (ORCID: https://orcid.org/0000-0001-6263-9705)
- Tao Wang (ORCID: https://orcid.org/0000-0002-5728-6463)
- Min Wu (ORCID: https://orcid.org/0000-0003-2114-6343)
- Ming Lei (ORCID: https://orcid.org/0009-0003-2672-4015)
- Ching Shang
- Xu Wan
- Alex C.Y. Chang
- Yangyang Liu
- Yinlong Zhao
- Wei Han
- Yueheng Wu
- Andrew C.H. Chang
- Junfeng Zhang
Institutions
- Shanghai Jiao Tong University (CN)
- Shanghai Ninth People's Hospital (CN)
- Shanghai East Hospital (CN)
- Guangdong Academy of Medical Sciences (CN)
- Io Therapeutics (United States) (US)
- Stanford University (US)
Publication Details
- Journal
- EBioMedicine
- Published
- 2026-03-09
- DOI
- https://doi.org/10.1016/j.ebiom.2026.106203
- Primary Topic
- Telomeres, Telomerase, and Senescence
- Type
- article
- Field-Weighted Citation Impact
- 0.00